Please enable Javascript
Patrick Daly
Patrick Daly is an Assistant Editor at AMC Media Group.
Articles by Patrick Daly
Data Support Front-Line Rituximab in Advanced, Low-Tumor Burden Follicular Lymphoma
Patrick Daly
Follicular Lymphoma
|
January 7, 2025
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
Read More
Ziftomenib, Venetoclax, Azacitidine in Pediatric Relapsed or Refractory Acute Leukemia
Patrick Daly
Acute Myeloid Leukemia
|
December 23, 2024
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
Read More
Alternating Venetoclax Regimens Strategy for Newly Diagnosed AML
Patrick Daly
Acute Myeloid Leukemia
|
December 23, 2024
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
Read More
Revumenib Maintains Efficacy in KMT2A-r Acute Leukemias
Patrick Daly
Acute Lymphoblastic Leukemia
|
December 23, 2024
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
Read More
Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial
Patrick Daly
Acute Myeloid Leukemia
|
December 23, 2024
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Read More
Early Signs of Activity Observed for Tagraxofusp Plus Decitabine in MDS, CMML
Patrick Daly
Meeting News
|
December 20, 2024
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Read More
Data Suggest Azacitidine, Nivolumab Is Best Immunotherapy Regimen for MDS
Patrick Daly
Meeting News
|
December 20, 2024
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
Read More
CPX-351 Plus Ivosidenib in IDH1-Mutated AML or MDS
Patrick Daly
Acute Myeloid Leukemia
|
January 17, 2025
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
Read More
Venetoclax Combination as Induction Therapy in AML and MDS
Patrick Daly
Acute Myeloid Leukemia
|
December 20, 2024
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
Read More
Long-Term Outcomes of Tisagenlecleucel in Follicular Lymphoma
Patrick Daly
Transplantation & Cellular Therapy
|
December 7, 2024
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Read More
Inhibition of Caspase-1 Improves CAR T-Cell Safety, Efficacy
Patrick Daly
Transplantation & Cellular Therapy
|
December 7, 2024
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Read More
Tapotoclax Is Safe after HMA Failure in MDS
Patrick Daly
Myelodysplastic Syndromes
|
December 5, 2024
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
Read More
Study Suggests ESAs Have High Rates of Failure in Lower-Risk MDS
Patrick Daly
Myelodysplastic Syndromes
|
December 5, 2024
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Read More
Oral Azacitidine Equivalent to Subcutaneous Formulation
Patrick Daly
Myelodysplastic Syndromes
|
December 5, 2024
Oral azacitidine plus cedazuridine achieved pharmacokinetic equivalence to subcutaneous azacitidine in MDS and MPN.
Read More
Paper Characterizes Optimal Treatments for NPM1-Mutated Myeloid Neoplasms
Patrick Daly
Myelodysplastic Syndromes
|
December 5, 2024
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
Read More
Long-Term Outcomes of CAR T-Cell Therapy in Patients With CLL
Patrick Daly
Chronic Lymphocytic Leukemia
|
November 27, 2024
Anti-CD19 CAR T-cell therapy appeared to cure a significant number of patients with relapsed or refractory CLL.
Read More
Dr. Usmani Highlights Myeloma Presentations from SOHO 2024
Saad Z. Usmani, MD, MBA, FACP
The HemOnc Pulse
|
November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Listen Now
Pivekimab Sunirine Shows Promise for AML in Phase I/II Trial
Patrick Daly
Acute Myeloid Leukemia
|
November 12, 2024
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Read More
Isolating CD34-Positive Samples: MRD Analysis in MDS
Patrick Daly
Meeting News
|
November 4, 2024
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Read More
Covering MDS Updates at SOHO 2024 With Dr. Venugopal
Sangeetha Venugopal, MD
The HemOnc Pulse
|
November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Listen Now
Load More